

**RECEIVED
CENTRAL FAX CENTER**

FEB 25 2004

Attorney's Docket 037003-0307368
Client Reference: 1997-30-0568D2**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****OFFICIAL**In re PATENT APPLICATION of:
NABIL HANNA ET AL.

Confirmation No:

Application No.: 10/743,739

Group Art Unit: Unassigned


Filed: December 24, 2003

Examiner: Unassigned

Title: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING
NEOPLASTIC OR CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING
HEMATOPOIESISCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**CERTIFICATION OF FACSIMILE TRANSMISSION
UNDER 37 C.F.R. §1.8**

I hereby certify that the following papers are being facsimile transmitted to the Patent and Trademark Office at (703) 872-9306 on the date shown below: Information Disclosure Statement, PTO-1449 (3 pages, including cover sheet)

PILLSBURY WINTHROP LLP

THOMAS A. CAWLEY, JR. PH.D.
Reg. No. 40944Date: February 20, 2004
P.O. Box 10500
McLean, VA 22102
Telephone: (703) 905-2000
Facsimile: (703) 905-2500

(Certification of Facsimile Transmission—page 1)

Docket Number: 037003-0307368

PATENT APPLICATION

Client Reference: 1997-30-0568D2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of HANNA et al.

Group Art Unit: Unassigned

Application No.: 10/743,739

Examiner: Unassigned

Filed: December 24, 2003

Confirmation No.:

For: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC
OR CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING
HEMATOPOIESIS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
CENTRAL FAX CENTER

FEB 25 2004

OFFICIAL

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. The references were cited by the applicant or examiner during the prosecution of U.S. Application No. 09/853,581, filed May 14, 2001, and/or U.S. Application No. 08/933,359, filed on September 18, 1997, to which the present application claims priority pursuant to 35 U.S.C. § 120. Thus, copies of the references listed in the attached PTO-1449 are not attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the filing date of the application and before the mailing date of the first official action on the merits in the present application. No certification or fee is required.

Respectfully submitted,



Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944

Date: February 20, 2004
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/JBM:ntb

30427614v1

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty Dkt. No.	M#	Client Ref.
	0307368	1997-30-0568D2
Applicant: HANNA et al.		
Appin. No.: 10/743,739		
Filing Date: December 24, 2003		
Examiner: Unassigned		Group Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: February 20, 2004

Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR 5,585,103	12/1996	Raychaudhuri			
	BR 5,695,770	12/1997	Raychaudhuri			
	CR					
	DR					

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT POSSESSION						Abstract		Readily Available		
		Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclose	No
	ER									
	FR									
	GR									
	HR									
	IR									
	JR									
	KR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

LR	Hallinan et al., "Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs," <i>J Med Chem</i> , 1996, 39:609-613
MR	Oka et al., "PGE2 receptor subtype EP1 antagonist may inhibit central interleukin-1 β -induced fever in rats," <i>The American Physiological Society</i> , 1998, R1762-1765.
NR	Isaac et al., "Successful treatment of established rat prostate cancer by transforming growth factor-B1 antisense transfected tumor vaccine," <i>J Urology</i> , 1997, 157:270.
OR	Murphy et al., "Differential effects of growth hormone and prolactin on murine T cell development and function," <i>J Exp Med</i> , 1993, 178:231-6
PR	Richards et al., "Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas," <i>Cell Immunol</i> , 1998, 184:85-91
QR	Jiayin et al., "Clinical application and potential of TGF β ," Beijing Institute of Basic Medical Sciences (thesis), May 1997, pp 135-40
RR	Wojtowicz-Praga et al., "Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2," <i>J Immunol</i> , 1996, 156(3):169-175
SR	Arteaga et al., "Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression," <i>J Clin Invest</i> , 1993, 92:2569-2576
TR	Hoefer et al., "Anti-(transforming growth factor beta) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice," <i>Cancer Immunol Immunother</i> , 1995, 41:302-306

Examiner

Date Considered:

*EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.